Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30913264 | 0.96 | ALDH1A1 (0.45) | CPB2ERAP2ERAP1LNPEPALDH1A1 | |
| SCHEMBL1711325 | 0.95 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711732 | 0.95 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711738 | 0.95 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711321 | 0.95 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| Hydrochloric Acid SCHEMBL11366046 | 0.93 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL29782763 | 0.92 | FOLH1 (0.51) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL30973961 | 0.90 | FOLH1 (0.56) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL31257001 | 0.90 | CPB2 (0.45) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL30974002 | 0.90 | BACE1 (0.51) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | claimed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | claimed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | claimed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | disclosed |
| CN-118873678-A | Antibody-conjugated drugs and uses thereof | 泰励生物科技（上海）有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | TNFRSF9, F13B, FCGR1A | CPB2 971/4885ERAP2 1982/4885ERAP1 1575/4885 |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | EPCAM, CNTN1, STX18 | CPB2 2276/4885ERAP2 3249/4885ERAP1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.